Description
Technical & Manufacturing Relevance:
A critical pharmaceutical raw material source for the semi-synthetic production of paclitaxel (taxol) and related anticancer agents.
Leaves are the preferred sustainable source for taxane precursors; bark use is highly restricted due to ecological concerns.
Requires strict GMP control, traceability, and controlled extraction owing to toxicity and regulatory sensitivity.
Not used as a conventional nutraceutical; applications are limited to pharmaceutical intermediates, research, and regulated oncology supply chains.
Extraction typically involves hydroalcoholic or organic solvent systems followed by advanced purification.
Applicable Dosage Forms:
Not supplied as finished dosage forms
Used as:
Pharmaceutical intermediate
API precursor for anticancer drug manufacturing
Research and development material
Pharmacopoeial / Quality Notes:
Taxane intermediates aligned with USP / Ph.Eur. / ICH Q7 requirements (when supplied as pharmaceutical raw material)
Typical quality parameters:
Assay: 10-deacetylbaccatin III (HPLC)
Residual solvents: ICH Q3C compliant
Heavy metals and pesticide residues within stringent pharmaceutical limits
Full traceability and batch documentation mandatory
End-use restrictions apply depending on importing country regulations.
Animal-Origin Declaration:
100% plant origin. No animal-derived ingredients.
Manufacturing Support:
Offered only for regulated pharmaceutical and research applications, subject to legal clearance, end-use declaration, and regulatory approval.
Support includes contract extraction, purification, and supply of standardized taxane intermediates, along with complete documentation such as COA, MSDS, TDS, impurity profile, stability data, GMP compliance statements, and export-control documentation.
Suitable for global pharmaceutical distribution where permitted by law and environmental regulations.
